The inaugural edition of Nucleic Acid Insights features a wide variety of stakeholders from across the nucleic acids space sharing their perspectives on recent progress, current challenges, and future directions in the field.
Confirmed contributors to this special edition include:
- Floris Engelhardt, CEO, Kano Therapeutics
- Jane A. Healy, VP, Head of Oncology Early Clinical Development, Merck & Co, Inc.
- Robert Langer, David H. Koch Institute Professor, MIT
- John Lewis, CEO, Entos Pharmaceuticals
- Paolo Martini, CSO, International Therapeutics Research Centers, Founder of Moderna Rare Diseases, Moderna
- Chris Mason, Professor of Cell and Gene Therapy, Advanced Centre for Biochemical Engineering, University College London
- Myriam Mendila, Chief Development Officer, Curevac
- Nizar Saad, Assistant Professor, The Ohio State University Medical School; Department of Pediatrics, Nationwide Children’s Research Institute
- Matthew Scholz, CEO, Oisin Biotechnologies
- Hartaj Singh, Managing Director, Oppenheimer & Co. Inc.
